ESAB (ESAB) Q1 2026 earnings review
M&A Masks Organic Contraction and Margin Compression
ESAB achieved record first-quarter sales of $746 million (+10% YoY), but the top-line growth was entirely purchased. Core organic sales actually contracted by 1.1%, while recent acquisitions (primarily EWM) contributed 6.6% to core growth. This heavy M&A integration, coupled with new supply chain disruptions tied to the conflict in Iran, dragged Core Adjusted EBITDA margins down 80 basis points to 19.0%. Management maintained an aggressive FY26 guidance that requires a significant acceleration in organic volumes, leaving little room for error as debt levels rise to fund the company's compounder strategy.
🐂 Bull Case
Acquisitions like EWM and Aktiv are growing at double-digit rates, validating the company's compounding strategy and effectively filling the void left by organic stagnation.
Adjusted free cash flow jumped 30% YoY to $39.5M, demonstrating ESAB's ability to extract cash from working capital even while integrating dilutive assets and managing supply chain shocks.
🐻 Bear Case
Core organic growth reversed to a 1.1% decline globally. Reaching the reiterated FY26 organic target of 2-4% growth will require a massive demand inflection that is not currently visible.
Core Adjusted EBITDA margin compressed from 19.8% to 19.0% YoY. The promised synergies from EWM are currently being outweighed by integration friction and geopolitical supply chain costs.
⚖️ Verdict: ⚪
Hold. The acquisition engine is working exactly as intended, but the underlying organic deterioration and margin compression suggest the core business is under elevated pressure. We wait for evidence of organic acceleration.
Key Themes
Data Contradicts Positive Regional Narrative
Management's press release explicitly claimed the U.S. is 'accelerating behind our new and innovative product launches' while Europe and Asia performed 'in line with expectations.' However, the data reveals a different story: Americas core organic sales declined 0.7% YoY, and EMEA & APAC reversed into a 1.5% organic contraction. Describing negative organic growth as 'accelerating' because it is slightly better than the severe tariff-driven drops of mid-2025 is overly optimistic.
Geopolitical Shocks Impacting Profitability
The conflict in Iran introduced tangible macro headwinds this quarter. Management cited these supply chain pressures and input cost escalations as a direct driver for the 80 bps compression in Core Adjusted EBITDA margins. While the company intends to implement pricing and operational actions to fully offset this, there will be a lag before these measures take effect.
Surging Debt Burden from M&A Spree
ESAB's aggressive acquisition strategy is ballooning its balance sheet. Long-term debt spiked to $2.03 billion, up 65% from $1.23 billion at the end of FY25, driven by the $1.0 billion drawdown on Senior Notes. Consequently, Q1 net interest expense jumped 52% YoY to $25.6M. This creates elevated leverage risk as the company prepares to close the $1.45B Eddyfi acquisition mid-year.
EWM and Aktiv Proving Highly Accretive to Top-Line
Despite margin dilution during integration, the M&A assets are performing robustly. EWM and Aktiv both posted double-digit growth in the quarter. The EWM portfolio integration is running ahead of schedule, validating management's strategy to shift the business mix toward higher-margin, heavy industrial automation equipment.
EBX Process Defending Cash Generation
Despite margin headwinds and supply chain chaos, the ESAB Business Excellence (EBXai) system continues to protect cash flows. Adjusted free cash flow grew to $39.5M, supported by a $40M reduction in inventory build-up and $39.6M in positive accounts payable adjustments. Working capital discipline remains a bright spot.
Product Innovation Stabilizing the Americas
While overall Americas organic growth was slightly negative (-0.7%), this marks a substantial stabilization from the steep 7.2% contraction seen in Q2 2025. This normalization was driven by market reception to new product launches, highlighting the importance of the company's refreshed equipment product lines.
Other KPIs
Decelerating. Gross margin contracted 70 basis points from 37.6% a year ago. Cost of sales outpaced net sales growth (11.2% vs 9.9%), indicating that pricing actions have not yet caught up with the inflationary pressures from Middle East supply chain disruptions.
Accelerating on a reported basis (+15.0% YoY). The segment was heavily lifted by the EWM acquisition (contributing 11.7% to growth) and favorable foreign currency translation (+6.1%). Core organic volume in the region actually fell 1.5%.
Guidance
Accelerating significantly versus the -1.1% printed in Q1. Achieving the midpoint (3.0%) implies a drastic volume recovery in the final three quarters of the year, relying heavily on pricing actions taking hold and industrial end-markets waking up.
Accelerating. The midpoint of $585M implies a ~8.3% YoY growth compared to FY25's $540.0M. Attaining this will require margins to step back up toward the >20% historical average as EWM integration friction fades and Iran-conflict pricing offsets materialize.
Accelerating. Midpoint of $5.80 represents roughly 10% YoY growth from FY25's $5.27. Note: This guidance strictly excludes any impact from the incoming Eddyfi acquisition or its associated financing costs.
Key Questions
Bridging the Organic Gap
Core organic growth was negative 1.1% in Q1 across both major geographies. What specific end-market indicators or backlog visibility gives you the confidence to reiterate the 2% to 4% full-year organic growth target?
Margin Recovery Timeline
With Core Adjusted EBITDA margins compressing 80 bps due to EWM dilution and the Iran conflict, what is the exact cadence for pricing actions to offset these costs, and will margins return to 20%+ by Q3?
Leverage Ceiling Post-Eddyfi
Long-term debt nearly doubled to over $2 billion this quarter. Once the $1.45B Eddyfi acquisition closes mid-year, what is the anticipated peak net leverage ratio, and will debt paydown completely replace share repurchases in the near term?